Summary
- Three French regional pharmacovigilance centres analysed 41 cases of non-infectious pulmonary disease attributed to hydroxycarbamide, recorded in the French pharmacovigilance database between 1988 and 2019.
- Their analysis showed that onset occurred after a period varying from a few months to several years, and sometimes had a fatal outcome.
©Prescrire 1 June 2022
Source: "Hydroxycarbamide: interstitial lung disease" Prescrire International 2022; 31 (238): 160. Free.
Enjoy full access to Prescrire International, and support independent information
|